logo

Biondvax Pharmaceuticals Ltd. (BVXV)



Trade BVXV now with
  Date
  Headline
9/20/2022 6:21:45 AM BiondVax Pharma Provides Updates Related To Strategic Research Collaboration With Max Planck And UMG
8/25/2022 7:38:38 AM BiondVax Pharmaceuticals Q2 Net Loss/shr NIS0.02 Vs. Loss/shr NIS0.03 Last Year
6/7/2022 8:43:06 AM BiondVax Receives Supportive Scientific Advice From Paul Ehrlich Institute For COVID-19 NanoAb Development Plans
12/27/2021 4:06:37 PM BiondVax Pharma Appoints Jay Green To Board Of Directors
12/27/2021 6:46:50 AM BiondVax Announces Pricing Of 3.81 Mln ADSs Follow-on Underwritten Offering At $2.36 Per ADS For About $9.0 Mln
12/22/2021 7:13:14 AM BiondVax Signs Agreements For Development And Commercialization Of Nanosized COVID-19 Antibody Therapy; Stock Surges
10/19/2021 8:00:24 AM BiondVax, Max Planck, UMG To Enter Into 5-year Research Collaboration Incl Option For BiondVax To License VHH Antibodies
6/23/2021 6:09:18 AM BiondVax Q1 Loss Per Share NIS 0.02 Vs Loss NIS 0.01 Last Year
1/29/2021 8:05:32 AM BiondVax Announces Pricing Of $12.1 Mln Follow-on Underwritten Offering Of American Depositary Shares
1/28/2021 7:50:31 PM BiondVax Announces Launch Of Proposed Underwritten Follow-on Offering Of ADSs
1/21/2021 7:17:26 AM BiondVax Appoints Amir Reichman As CEO, Effective March 2, 2021